CN Bio
CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.
Tech Stack (30 technologies)
Frequently Asked Questions
What technologies does CN Bio use?+
CN Bio uses 30 technologies including CookieFirst, Genesis theme, Google Analytics.
What industry is CN Bio in?+
CN Bio operates in the Biopharma industry.
Where is CN Bio based?+
CN Bio is headquartered in United Kingdom.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026